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Abstract
OBJECTIVE: To evaluate the clinical efficacy of saf-
flower yellow injection combined with convention-
al therapy in treating unstable angina pectoris.
METHODS:We searched online databases: Chinese
journal full-text database, China National Knowl-
edge Infrastructure, Wanfang database, Chinese
journal full-text database, Pubmed, ScienceDirect,
Embase, and the Cochrane Library with manu-
al-screening of relevant literature. Eligible random-
ized controlled trials (RCT) on angina pectoris were
included. We conducted meta-analysis using the
RevMan 5.1 software from The Cochrane Collabora-
tion. We treated the relief rate of angina symptoms
and electrocardiograph (ECG) as evaluation.
RESULTS: Seven articles, including in 1134 pa-
tients, were enrolled after the evaluation. There
was no significant heterogeneity among the stud-
ies (χ2=1.08, df=6, P=0.98, I2=0%). The safflower yel-
low injection with conventional therapy has a high-
er effective rate than the control group in relieving
the symptoms of angina pectoris [odds ratio (OR)=
2.95, 95% (CI) (1.81, 4.81)] and improving ischemic
ECG [OR=2.85, 95% CI (1.67, 4.86)]. The difference
was statistically significant in the "80 mg dosage"
and "100 mg dosage" subgroups (P<0.05) for im-
proving clinical symptoms and ECG. The funnel
graphic was nearly symmetrical. Sensitivity analysis
suggested that the results were stable.
CONCLUSION: Safflower yellow injection as an ad-
junct therapy with conventional drugs shows ad-
vantages in easing the clinical symptoms of unsta-
ble angina and improving ECG over basic therapy
alone. However, the conclusions should be inter-
preted with care until more high-quality RCTs are
reported.
© 2013 JTCM. All rights reserved.
Key words: Safflower yellow injection; Angina, un-
stable; Meta-analysis
INTRODUCTION
Coronary artery disease is heart disease with myocardi-
al ischemia and hypoxia caused by coronary atheroscle-
rosis or stenosis. These symptoms coupled with coro-
nary artery spasms and changes are collectively known
as coronary heart disease.1 The incidence of angina pec-
toris has increased in recent years with improving liv-
ing standards of Chinese, dietary changes,2,3 and in-
creased stress.4,5 Angina pectoris has become the lead-
ing cause of death in China.6 The nomenclature and di-
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agnostic standards of ischemic heart disease were pub-
lished by World Health Organization in 1979.7 WHO
divided ischemic heart disease into five types including
occult coronary heart disease, angina, myocardial in-
farction, ischemic cardiomyopathy and sudden-death.
Angina is further divided into three types: exertional
angina, spontaneous angina, and mixed angina. Exer-
tional angina includes stable exertional angina pectoris,
the first episode of angina pectoris and progressive angi-
na pectoris. Except stable exertional angina, the rest are
unstable. These subcategories are included in the "un-
stable angina diagnosis and treatment recommenda-
tions"8 developed by the Chinese Medical Society of
Cardiology in 2000.
In recent years, safflower yellow injection (SYI) has
been widely used for treating unstable angina pectoris.
There have been many clinical trials reported confirm-
ing its effectiveness and safety.9-15 Honghua (Flos Car-
thami), a Traditional Chinese Medicine, can activate
blood and dredge the meridians, removing stasis and re-
lieving pain.16 Ben Cao Hui Yan said, "Honghua (Flos
Carthami) is a medicine breaking blood stasis, activat-
ing blood circulation, mediating blood, and adjusting
blood." 17 Modern pharmacological studies have shown
that its main chemical ingredients "safflower yellow
pigment" have efficacy for some conditions. It can im-
prove myocardial energy metabolism, reduce ischemic
damage,18 and inhibit the activation of neutrophils.19
Some researchers report that it can soften artery athero-
sclerosis,20 reduce myocardial ischemia,21 and resist in-
flammation by inhibiting nitric oxide (NO) and prosta-
glandin E2 (PGE2).22 SYI was made with safflower yel-
low pigment as the main ingredient. The common
route of administration of SYI are injection and pow-
der. Both were used in studies analyzed in this paper.
In this study, we performed an analysis of multiple in-
dependent clinical randomized controlled trials (RCTs)
to estimate the odds ratio (OR) and to systematically re-
view the efficacy of SYI combined with conventional
therapy in treating unstable angina.
MATERIALS ANDMETHODS
Data sources
We searched the literature according to the "Cochrane
Handbook for Systematic Reviews of Interventions" pub-
lished by The Cochrane Collaboration. We screened the
online databases: Chinese journal full-text database
(1989-August 2012), China National Knowledge Infra-
structure (CNKI) (1979-August 2012), Wanfang Data-
base (1977-August 2012), Pubmed (1950-2012), Sci-
enceDirect (1823-2012), Embase (2009-2012), and
the Cochrane Library (1948-2012). We also performed
some manual-screening of relevant literature. The last
search was performed on 30 August 2012.
Search strategies
We used terms depending upon the working language
of the databases. Terms we used were: "Carthamus tinc-
torius injection," "Honghua (Flos Carthami)", "SYI,"
and "unstable angina". The following search strategy
was used in PubMed and other English databases: (a)
carthamus tinctorius injection; (b) Honghua (Flos Car-
thami); (c) SYI; (d) 1 in all fields; (e) 2 in all fields; (f )
3 in all fields; (g) 1 'OR' 2 'OR' 3.
For searching the CNKI data and other Chinese data-
bases, the following search strategy was used: (a) SYI;
(b) unstable angina; (c) 1 in all fields; (d) 2 in all fields;
(e) 1 'AND' 2.
Two reviewers independently read the title and ab-
stract, and then read the full text after ruling out litera-
ture that obviously did not meet the inclusion stan-
dards. Then, a cross-check was conducted, and any dis-
agreement was resolved through discussion or third-
party opinions.
Inclusion criteria
We developed the inclusion and exclusion criteria ac-
cording to the Cochrane Collaboration Handbook crite-
ria. (a) Trials must be a randomized, controlled design.
(b) Diagnosis of unstable angina should follow the "un-
stable angina diagnosis and treatment recommenda-
tions" developed by the Chinese Medical Society of Car-
diology in 2000,8 or standards developed by the Ameri-
can College of Cardiology and American Heart Associa-
tion.23 (c) Selected cases should be without severe organ-
ic diseases or complications. (d) The control group was
given conventional treatment for the secondary preven-
tion of coronary heart disease such as nitrates, aspirin,
and adrenergic receptor blockers, statins, and angioten-
sin II receptor antagonists. However, the experimental
group was given SYI based on the conventional treat-
ment. (e) There was no use of positive drugs such as
Danshen injection, safflower injection, Hongdan injec-
tion and Chuanxiong injection. (f ) Powder for injection
ranged from 50-150 mg, without limits on the manufac-
turer or dosage forms. (g) The signals should be at least
one of the symptoms of angina response rate and electro-
cardiograph (ECG) improvement rate, and should meet
the evaluation standard.
Exclusion criteria
The exclusion standards were: (a) unpublished litera-
ture; (b) no control group set in the documents; (c)
quasi-experimental design; (d) no clearly identified re-
sult assessment; (e) repeated original literature; or (f )
multiple contributions of one manuscript.
Symptom improvement standards
We performed the standard of symptom improvement
according to the "Guidelines for clinical research ofTradi-
tional Chinese Drug treating angina pectoris."24 After a
course of treatment, the improvement of symptoms
should be at least 80%, or nitroglycerin tablet consump-
tion should decrease by 80% (i.e., significant symptomat-
ic improvement). The improvement of symptoms
should be at least 50%, or nitroglycerin tablet consump-
tion should decrease by 50% (i.e., basic symptomatic
improvement).
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ECG improvement standard
We set out the ECG improvement standard according
to the "Diagnosis and treatment guidelines for Chinese
common cardiovascular and cerebrovascular disease."25
If the ST segment and T wave returned to normal then
there was significant ECG improvement. If the ST seg-
ment recovered at least 0.05 mv, and the T wave inver-
sion decreased more than 50% there was basic ECG
improvement.
Data synthesis and statistical analysis
We used the Revman 5.1 software provided by "The
Cochrane Collaboration" to analyze the collected data.
An OR with 95% confidence intervals (CI) was chose
to count data. A fixed-effect model of the Man-
tel-Haenszel method was used to pool these OR if
there was no significant heterogeneity. Subgroup analy-
ses were performed to explore more information. We
used the Q test and I2 test to analyze the heterogeneity
across studies. A condition of P<0.05 was defined as a
signal of heterogeneity. A condition of I2>50% suggest-
ed the data might not be probable to be combined.26 In
addition, we created a funnel plot to analyze potential
publication bias,27 and tested the stability of the results
by using sensitivity analysis.
Risk of bias in individual studies
According to the "Cochrane risk of bias tool"28 and
"CONSORT 2010 checklist,"29 two reviewers indepen-
dently assessed the quality of included studies in items
such as randomization, allocation concealment, and
blinding.
RESULTS
Search results
The process of study selection is shown in Figure 1.
Overall, we collected 92 articles in Chinese, 354 in
English, and 5 through manual screening. We screened
28 papers for full text after we sieved out the obviously
ineligible and repeated documents. We screened out 21
of these studies for reasons such as lack of control
group, and multiple contributions of one manuscript.
Finally, seven articles were included in this review.
Figure 1 Process of searching and screening study
CNKI: China National Knowledge Infrastructure;WF:Wangfang data; VIP: Chinese journal full-text database.
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Characteristics of included trials
All enrolled patients were diagnosed as having unstable
angina pectoris. The control group was given the basic
treatment widely recognized as valid, and the experi-
mental group was given SYI based on the same essen-
tial treatment. SYI dosage ranged form 50-150 mg
once a day intravenously, with a course of 14-15 days
(only "Liu JH 2009" used 10 days). The screened re-
sults by the two reviewers were the same (Table 1).
Quality assessment
We included 1134 subjects in seven papers, with aver-
age samples of 162. There were 554 total patients in
the trial group and 580 in the control group. All stud-
ies showed comparability or no significant difference
between the two groups (P>0.05). One study de-
scribed the random methods,11 and another included
adverse drug reactions.10 All studies did not drop out of
the clinical trails (Table 2).
Information from the CONSORT 2010 checklist con-
formity is shown in Table 3. The rates (total items actu-
ally reported/total number of items in CONSORT
2010) were: 100% for title and abstract, 71.43% for in-
troduction, 85.87% for results, 66.67% for discussion,
and 29.4% for methods. The rate of abiding by overall
CONSORT 2010 of all included studies was 44.02%,
indicating 44.02% of all items were satisfactorily re-
ported on average.
Table 2 Characteristics of included trials in the meta-analysis
Study
Jin C 20119
Wei ZF 201010
Yu XW 201111
Liu JH 200912
Zhou SJ 201113
Tang Q 201114
Xia HZ 201015
Angina symptom relief
T
60
301
39
26
35
41
30
C
53
322
35
15
28
33
27
ECG improvement
T
59
NA
38
25
34
36
NA
C
52
NA
25
15
28
32
NA
Adverse reaction
No
Yes
No
No
No
No
No
Notes: ECG: electrocardiograph; T: test group; C: control group; NA: no data available.
Table 3 Total number of items compliant with the "CONSORT 2010 checklist"
Author
Jin C9
Wei ZF10
Yu XW11
Liu JH12
Zhou SJ13
Tang Q14
Xia HZ 201015
Total of each field
Rated percentage (%)
Title and
abstract
2
2
2
2
2
2
2
14
100.00
Introduction
1
2
1
1
2
1
2
10
71.43
Methods
5
5
6
5
5
5
4
35
29.41
Results
6
6
6
6
6
6
5
41
58.57
Discussion
2
2
2
2
2
2
2
14
66.67
Other
information
0
0
0
0
0
0
0
0
0.00
Total of each
study
16
17
17
16
17
16
15
114
44.02
Notes: rated percentage is total items actually reported in all studies/total number of items in CONSORT 2010 checklist.
Table 1 Characteristics of included trials in the meta-analysis
Notes: T: test group; C: control group. SYI: Safflower yellow injection.
Study
Jin C 20119
Wei ZF 201010
Yu XW 201111
Liu JH 200912
Zhou SJ 201113
Tang Q 201114
Xia HZ 201015
Age
45-75
45-78
60-78
42-78
45-75
52-76
60±8.5
Included number
Ta
65
310
41
28
38
43
31
Cb
65
348
39
20
38
42
31
Treatment
(day)
14
10-14
15
10
14
14
14
Dosage of SYI mL
(mg)
150
100
100 (80)
50
100 (80)
150
100
Positive
control
None
None
None
None
None
None
None
Concomitant
medication
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
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The Cochrane risk of bias tool gave risk of bias within
studies in Figure 2, 3: low bias in incomplete outcome
data, unclear bias in selective outcome reporting, blind-
ing of participants, personnel and outcome assessors,
sequence generation (except for study 11), allocation
concealment and other sources of bias.
Symptoms of angina
Meta-analysis of the seven studies showed no heteroge-
neity between studies (χ2=1.08, df=6, P=0.98>0.05, I2=
0% ). Therefore, the fixed effects model (M-H: Man-
tel-Haenszel formula) could be taken for analysis.
In Figure 4, the summary odds ratio (OR) of the num-
ber of angina attacks decreased by ≥50% was 2.86,
95% CI (1.78, 4.59). The diamond in the forest plot is
on the right side of the middle line. The overall effect
of test Z=4.35, P<0.000 01 tells that efficacy of SYI
with basic therapy on the symptoms of angina pectoris
was much better than the control. Posted bias assess-
ment of the included studies is shown in Figure 5. The
funnel graphics are almost symmetrical, suggesting no
publication bias.
ECG improvement
Among the five studies9,11-14 there were 419 patients,
with 215 in the test group and 204 in the control
group. No obvious heterogeneity existed among the
studies (χ2=2.94, df=4. P=0.57>0.05, I2= 0%). There-
fore, we used the fixed effect model analysis (MH Fixed
method) to analyze.The results are shown inFigure 6.
The diamond is in the right side of the middle line.
The efficacy of SYI on ECG was significantly superior
to that of drugs in the control group [OR=2.85, 95%
CI (1.67, 4.86)] (Z=3.84. P=0.00001).
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blingding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figure 2 Analysis on the risk of bias of included trails
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Figure 3 Summary of the risk of bias of trails included
Figure 4 Meta-analysis results of symptoms of angina
SYI: Safflower Yellow Injection.
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Subgroup analysis
We made the subgroup analysis according to the dos-
age of injection. Studies were divided into four sub-
groups: 50 mg dosage,12 80 mg,11,13 100 mg,10,15 and
150 mg.9,14 The results showed that SYI with conven-
tional therapy had a higher effective rate than routine
therapy alone in the control group, except the sub-
group "50 mg dosage" (Z=1.63, P=0.10). Five studies
were divided into three subgroups about ECG improve-
ment. Subgroup "80 mg dosage" had a higher effective
rate than that in the control group on ECG improve-
ment (Z=3.30, P=0.001). The difference was insignifi-
cant in subgroup "50 mg dosage" and "150 mg dos-
age" on ECG improvement (P>0.05) (Figure 7, 8).
Sensitivity analysis
To perform the sensitivity analysis, we replaced fixed
Figure 6 Meta-analysis results of electrocardiograph improvement
Figure 7 Subgroup analyses on symptoms of angina
OR
0
0.5
1
1.5
2 0.01 0.1 1 10 100
SE (log [OR])
OR
Figure 5 Posted bias assessment of the included studies
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effects methods with random effects methods, exclud-
ed literature which had the largest number of samples,10
and short treatment course.10,12 As shown in Figure 9,
10, and 11: OR=2.85, 95% CI (1.77, 4.57); OR=2.97,
95% CI (1.63, 5.39); and OR=2.83, 95% CI (1.50,
5.33), respectively. OR values did not change signifi-
cantly under different interventions, suggesting the sta-
bility of this result.
Adverse reactions
Six studies described adverse reactions. Only one study
had minor side-effects including rash and dizziness,
which were improved by adjusting the medication drip
rate.
DISCUSSION
SYI is a product of Traditional Chinese Medicine.
However, the efficacy of the combined use of SYI and
basic therapy remains controversial. In China, it is com-
mon to use SYI with routine therapy to treat unstable
angina. However, no systematic review has been pub-
lished in English, which hinders SYI's ability to gain
worldwide recognition. We reviewed current RCTs to
provide evidence for the use of SYI as an adjunctive
therapy for unstable angina. Each study took broadly
accepted diagnostic standards to determine treatment
outcomes. In this study, we took the two signals of ef-
fects in symptoms and ECG improvement for analysis,
which fully reflect the effectiveness of treating unstable
angina pectoris. Meta-analysis is the best method of lit-
erature analysis in evidence-based medicine. It can save
costs and time integrating the data of multiple indepen-
dent studies to increase sample size and to improving
test performance.30 Moreover, it can provide clinicians
with evidence-based medical evidence to guide their
clinical practice. This meta-analysis showed that the ef-
ficacy of SYI combined with conventional therapy was
better than basic therapy alone in terms of relieving
symptoms of angina and ECG. From subgroup analy-
ses, the difference was statistically significant (P<0.05)
in the subgroup "80 mg dosage" and "100 mg dosage."
Therefore, we suggested that the dosage of SYI in treat-
ing unstable angina should be 80 or 100 mg. Sensitivi-
ty analysis suggested that the results were stable. How-
ever, further clinical trials need to be performed before
any firm conclusions can be drawn. Evidence from
these articles9-15 and our analysis suggest that conven-
tional therapy combined with SYI has an advantage in
treating unstable angina.
There are several limitations in this study. First, only
one study reported the randomization method.11 A lack
of descriptions of randomization methods and alloca-
tion concealment may have biased the results. Second,
blinding was not clearly described in any of the trials,
which may overestimate the efficacy of the treatment
group. In spite of the difficulty of implementing blind-
ing methods of TCM clinical research, it is necessary
to use blinding during the measurement of outcomes.
Third, there were variations in manufacturing stan-
Figure 8 Subgroup analyses on electrocardiograph improvement
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dards and two studies10,12 had a very short treatment
course. These factors may contribute to heterogeneity
among the studies. Nevertheless, the results proved to
be stable after excluding these reports (Figure 11).
Fourthly, the follow-up period is an important factor
for the medical efficacy for patients with unstable angi-
na pectoris. This meta-analysis included seven RCTs
with short follow-up periods, whichmay influence the re-
sult.More studies with longer follow-up periods are need-
ed to prove this trend. Fifthly, some studies reported the
signals such as blood lipids and blood viscosity.9,12-14 How-
ever, methodological heterogeneity31 may be caused by
different instruments. Therefore, these signals were not
used in our analysis. Finally, publication bias may exist
in the study. Although we thoroughly screened the
English database, there were no English studies. Addi-
tionally, all the studies are positive results. Some nega-
tive results may be unreported and therefore, are not in-
cluded in the review.
As most of the studies reviewed in the TCM field come
from China, Chinese researchers should formally train
in clinical trial design. Future trials should describe ran-
domization methods, allocation concealment, and
blinding methods during clinical research and measur-
ing outcomes. Otherwise, it is difficult to exclude the
possibility of biases in the assessment of clinical effica-
cy, symptom scores, and other outcome indexes. With-
drawal and follow-up data are also necessary. Publish-
ers play an important role in this effort as well. Re-
searchers should strictly obey "The Randomized Con-
trolled Experiment Report Specification-Consort,"32 es-
pecially in TCM clinical trials to provide quality evi-
dence for the second evaluation and to increase the
strength of the arguments.
This meta-analysis found that SYI combined with con-
ventional therapy for unstable angina is more effective
than basic therapy alone in terms of improving the
symptoms of angina and ECG. However, this conclu-
sion should be interpreted with care because of the low
quality of the included trials. More rigorous design,
large samples, multicenter, and high-quality RCTs
need to be performed before any firm conclusions can
be drawn.
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